Adipocyte-derived PGE$_2$ is required for intermittent fasting–induced Treg proliferation and improvement of insulin sensitivity

Chunqing Wang,1 Xing Zhang,1 Liping Luo,1 Yan Luo,1 Xin Yang,1 Xiaofeng Ding,1 Lu Wang,1 Huyen Le,1 Lily Elizabeth R. Feldman,1 Xuebo Men,2 Cen Yan,3 Wendong Huang,4 Yingmei Feng,1 Feng Liu,5 Xuexian O. Yang,6,7 and Meilian Liu1,7

1Department of Biochemistry and Molecular Biology, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA. 2Baodi Clinical College of Tian Jin Medical University, Tianjin, China. 3Department of Diabetes Complications & Metabolism Research, City of Hope, Duarte, California, USA. 4Metabolic Syndrome Research Center, Second Xiangya Hospital, Central South University, Changsha, China. 5Department of Molecular Genetics and Microbiology and 7Autophagy Inflammation and Metabolism Center for Biomedical Research Excellence, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA.

Introduction

Obesity, a disorder characterized by excess adiposity, has become a primary cause of insulin resistance, type 2 diabetes, and cardiovascular diseases. Adipose tissue (AT) expansion in obesity is mediated by increased volume of preexisting adipocytes (hypertrophy), generation of new small adipocytes (hyperplasia), or both. Pathological expansion of AT is accompanied by adipose hypoxia, angiogenesis, remodeling, and inflammation, thereby causing systemic insulin resistance and type 2 diabetes (1, 2). Intermittent fasting (IF), an eating pattern that involves periods of normal eating followed by restriction (founding), has gained attention as an effective approach to improve obesity-induced metabolic dysfunctions such as insulin resistance and type 2 diabetes (3–5). However, the mechanisms underlying the beneficial effects of IF on metabolic homeostasis are still poorly understood. This knowledge gap must be addressed to produce translational targets for antiobesity treatments in humans.

CD4$^+$Foxp3$^+$ Tregs are enriched in AT and are inversely correlated with obesity (6–8). AT Tregs exert antiinflammatory effects, and the reduction of AT Treg populations is crucially involved in the development of obesity-induced inflammation and substantial insulin resistance (6, 9, 10). Distinct from those Tregs in lymphoid and nonlymphoid tissue, AT Tregs are characterized by a distinguishable T cell receptor repertoire, chemokine profile, and chemokine receptors (6). Several intrinsic pathways, including PPARy,
IRF4, BATF, Stat3, and Stat6, play important roles in regulating development and activation of AT Tregs (9, 11–13). MHCIi in adipocytes is a critical determinant of the obesity-induced, adipose T cell subset switch (14, 15). In addition, cold stress has been demonstrated to induce activation of Tregs as well as development of beige adipocytes in AT (13). However, little is known about whether caloric restriction, such as IF, improves metabolic homeostasis by regulating Treg proliferation and activation.

Cyclooxygenase (COX), a rate-limiting enzyme responsible for the biosynthesis of prostaglandins (PGs), exists in 2 isoforms: COX-1, the constitutive form encoded by Ptgs1, and COX-2, the inducible form encoded by Ptgs2 (16). COX-2 oxygenates arachidonic acid and converts it into a number of PGs, including PGD$_2$, PGE$_2$, PGF$_2\alpha$, and prostacyclin (PGI$_2$), all of which exert diverse hormone-like effects via autocrine or paracrine mechanisms (16). The accumulated evidence shows that PGs modulate adipogenesis by acting as an agonist or analog of PPAR$\gamma$ (17). It has also been suggested that the COX-2/PG axis plays a critical role in regulating AT inflammation and obesity-induced insulin resistance (18–23). In addition, the COX-2/PG pathway is involved in thermogenic programming and WAT browning, although whether COX-2 is induced by cold and is correlated with obesity are still controversial (18, 24–27). On the other hand, while COX-2 expression is known to be induced by activation of lipolysis, a pathway that is stimulated by IF (21), whether adipocyte COX-2 is altered by IF and mediates IF-driven beneficial effects is unclear.

Here, we show that adipose COX-2 is suppressed by obesity in humans, and the decreased levels of COX-2 were restored by alternate-day fasting in obese rodents. Adipose-specific depletion of COX-2 leads to a significant decrease in the fractions of Tregs and CD206$^+$ macrophages and increased abundance of $\gamma\delta$T cells in AT, overall suppressing AT type 2 inflammation under normal chow diet (NCD) conditions. COX-2 deficiency resulted in adipocyte-suppressed, IF-induced Treg activation and insulin sensitivity via PGE$_2$-dependent mechanisms. In this study, we report that adipocyte-derived PGE$_2$ senses fasting and refeeding and mediates IF-elicted metabolic fitness. These findings provide a detailed and relevant basis for continued translational research regarding PGE$_2$ as a human anti-diabetes treatment.

**Results**

**COX-2 expression is suppressed by obesity, and this suppression is restored by IF in AT.** Adipose COX-2 plays a vital role in regulating inflammation and energy expenditure by controlling synthesis of PGs (18, 20–23). To investigate whether obesity affects the expression levels of adipose COX-2 in humans, we collected visceral fat samples from patients with obesity or overweight with BMI greater than 27 kg/m$^2$ and lean control participants with BMI less than 25 kg/m$^2$. Consistent with our previous finding that COX-2 is downregulated in white adipose tissue (WAT) of obese mice (26), we found that the protein and mRNA levels of COX-2 were significantly reduced in visceral fat of human participants with obesity (Figure 1, A–C). Interestingly, 15-cycle IF restored the protein and mRNA levels of COX-2 but not COX-1 in epididymal WAT (eWAT) and inguinal WAT (iWAT) of mice with diet-induced obesity (Figure 1, D–I). Consistent with this, the expression levels of COX-2 but not COX-1 in eWAT were also significantly upregulated by 3-cycle IF (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.153755DS1) and 15-cycle IF (Figure 1, J–L) in the mice fed a NCD, although the induction of COX-2 in iWAT was only observed in 15-cycle IF mice (Figure 1, M–O) but not in 3-cycle IF mice (Supplemental Figure 1, C and D). The results suggest a negative correlation of adipose COX-2 with obesity in humans and that adipose COX-2 may be involved in IF-driven metabolic benefits.

**Adipocyte-specific depletion of COX-2 attenuates PG production and promotes age-related adipogenesis.** To characterize the physiological role of adipocyte COX-2 in regulating adipose and systemic metabolism, we generated adipocyte-specific COX-2–KO mice by crossing COX-2–floxed mice and adiponectin-cre mice. The results showed that both protein and mRNA levels of COX-2 but not COX-1 in eWAT and iWAT, and not in muscle, liver, pancreas, or brain tissue, were markedly downregulated by adipocyte-specific depletion of COX-2 (Figure 2, A–C). A similar suppressing effect of COX-2 depletion on COX-2 was observed in adipocytes (Supplemental Figure 1E). COX-2 deficiency in adipocytes suppressed the basal and IF-induced secretion of PGE$_2$ in eWAT and iWAT (Figure 2D and Supplemental Figure 1, F and G). COX-2 deficiency also decreased the secretion levels of PGI$_2$ in WAT under basal and IF conditions (Figure 2E). PGD$_2$ levels were not significantly affected by COX-2 deficiency and IF even with a slight increase in KO eWAT (Supplemental Figure 1H).

Contrary to previous findings that global depletion of COX-2 led to fat loss (19), the COX-2–deficient mice displayed a slight increase in fat mass and total body mass under NCD conditions at the age...
of 3 months (Supplemental Figure 1I) but to a greater extent in 6-month-old mice (Figure 2, F–H). The increased fat mass occurred in eWAT and iWAT with a slight increase in brown adipose tissue (BAT) of 6-month-old COX-2–KO mice compared with control littermates (Figure 2, F–I). Moreover, adipocyte size in iWAT and eWAT was increased by adipocyte COX-2 deficiency (Figure 2, I–K). Consistent with this, COX-2–deficient mice exhibited slightly reduced glucose and insulin tolerance at 6 months of age but not at 3 months (Supplemental Figure 1, J–M). These data suggest that adipocyte COX-2 maybe a key regulator of WAT adipogenesis and function.

**Figure 1. COX-2 expression is suppressed by obesity and is induced by IF in AT.** The expression levels of COX-2 but not COX-1 in protein (A and B) and mRNA (C) were suppressed by obesity in visceral fat of human participants, compared with that of lean controls, despite a decrease in mRNA of PTGS2, a gene that encodes human COX-2. PTGS1 is a gene encoding human COX-1. Tubulin was used as the loading control. The expression levels of COX-2 but not COX-1 in protein (D and E) and mRNA (F) were markedly induced by IF in eWAT of mice with diet-induced obesity. The protein (G and H) and mRNA (I) levels of COX-2 in iWAT were also induced by IF despite the suppression of COX-1 in protein in obese mice. The upregulation of COX-2 expression by IF was also observed in eWAT (J–L) and iWAT (M and N) of NCD mice, although no significant effect was observed on the mRNA levels of both Ptgs2, a gene that encodes mouse COX-2, and Ptgs1, a gene that encodes mouse COX-1, in iWAT (O). We fed 6-week-old male mice a 45% HFD or NCD for 8 weeks, which was followed by Ad or IF for 30 days. All data in this figure were analyzed by t test and are presented as the mean ± SEM. *P < 0.05; **P < 0.01.
COX-2 deficiency in adipocytes suppresses Treg proliferation and type 2 inflammation in AT. To investigate the role of COX-2 in regulating AT inflammation, we performed flow cytometry analysis to examine whether deficiency of COX-2 in adipocytes alters adipose immune compartment at age 6 months, using the strategy described in Supplemental Figure 2A. Despite no significant decrease in CD4+, CD3+, CD8+, or CD45+...
T cells (Supplemental Figure 2, B–E), COX-2 deficiency decreased the frequency of CD4+Foxp3+ cells (Tregs) and the proportion of Tregs in CD4+ cells in eWAT (Figure 3, A–C), suggesting the antiinflammatory effect of COX-2 in adipocytes. Moreover, both the fraction of Siglec-5 CD11b+CD206+ cells and the proportion of CD206+ macrophages in total macrophages were suppressed by COX-2 deficiency (Figure 3, D–F), accompanied with an increased proportion of M1 (Siglec-5 CD11b+CD206+) in total macrophage, decreased total macrophages, and reduced fraction of eosinophils (Siglec-5 CD11b+) (Supplemental Figure 2, F–H). In addition, the fraction of γδT cells was increased by COX-2 deficiency in eWAT under NCD conditions (Figure 3, G–I).

Along this line, the mRNA levels of Treg markers, including Foxp3 and Gata3, were significantly decreased in COX-2–KO mice, while inflammatory factors Ifng and Il1b were upregulated with no significant effect on Il10, Il6, and Tnf (Figure 3J). In agreement with the antiinflammatory property of COX-2 in adipocytes, the medium from COX-2–KO adipocytes did not maintain AT Treg proliferation, as indicated by the number of Foxp3+CD4+ cells, the proportion of Ki67+ Tregs in total Tregs, and expression levels of Foxp3, Gata3, Hpgd, and Il10, but not Tgfb1 (Figure 3, K–M).

COX-2 in adipocytes is required for IF-driven metabolic improvement in AT inflammation and insulin sensitivity. The marked induction of COX-2 expression by IF in AT spurred us to investigate if COX-2 in adipocytes mediates IF-elicted metabolic benefits (Figure 1, D–I). COX-2–KO mice and control littermates (6 weeks old) were fed an HFD for 8 weeks and then underwent alternate-day fasting (24-hour fasting followed by alternating 24-hour periods with free access to food) for 15 cycles. We found that IF led to a robust decrease in fat mass, body mass, and fat cell size in AT, as well as smaller lipid droplets in BAT and liver tissue in HFD-fed control mice (Figure 4, A–C, and Supplemental Figure 3, A–C), and the total food intake for each cycle was similar among the ad libitum (Ad), IF, control, and KO groups (Supplemental Figure 3D). However, although COX-2–KO mice displayed an increase in body mass, fat mass, and fat cell size, the antiobesity effect of IF was retained in COX-2–KO mice (Figure 4, A–C, and Supplemental Figure 3, A–C). The suppressing effects of IF on fat percentage, iWAT mass, and fatty liver were attenuated by COX-2 deficiency (Figure 4, A and B, and Supplemental Figure 3, A and E). On the other hand, IF restored HFD-decreased frequency of Tregs and mRNA levels of Foxp3, Gata3, Tgfb2, and Tgfb3 accompanied by a decreased γδT cell fraction (Figure 4, D–H, and Supplemental Figure 3, F and G). In agreement with this, insulin-stimulated Akt phosphorylation at Thr308 in liver and eWAT, as well as glucose and insulin tolerance, were improved by IF in HFD-fed mice (Figure 4, I–L, and Supplemental Figure 3H). However, the improvement in AT inflammation, insulin action, and insulin sensitivity were suppressed in COX-2–KO mice concurrently with decreased fractions of Tregs and CD206+ macrophages and an increased γδT cell population (Figure 4, D–L, and Supplemental Figure 3, F–H). Depleting COX-2 in adipocytes suppressed IF-induced UCP1 and adiponectin expression and upregulated PPARγ expression levels in iWAT (Supplemental Figure 3I).

We asked if COX-2 induces thermogenic markers through VEGF and FGF21 pathways, given their role in fasting adaptive response and subsequent WAT browning (28–30). COX-2 deficiency had little effect on basal and IF-induced Vegf expression and Fgf21 transcription in iWAT (Supplemental Figure 3J). IF, however, suppressed transcription of proinflammatory genes Ifng and histocompatibility 2-class II antigen E beta (H2-Eb1) that have been shown to suppress AT Treg activation (14), which is independent of COX-2 in eWAT (Supplemental Figure 3J). Our results suggest that adipocyte COX-2 partially mediates IF-induced Treg proliferation and improved AT inflammation and insulin sensitivity, which may be obesity independent (Figure 4).

Adoptive transfer of Treg restores the impaired antiinflammatory response and insulin sensitivity in COX-2-deficient mice. To determine whether the decrease in the Treg fraction mediates COX-2 deficiency–induced insulin resistance, we adoptively transferred CD4+Foxp3+ Tregs from Foxp3-eGFP mice into either COX-2–KO mice or control littermates. The CD4+ GFP+ cells were selected from the isolated CD4+CD25+ cells and i.p. injected (1 × 106 cells/mouse) into male COX-2–KO and control mice fed an HFD for 8 weeks. BW measurement and glucose and insulin tolerance tests were performed 14 days after the injection. Despite having no significant effects on BW (Figure 5A), adoptive transfer of Tregs increased the resident GFP+ cells and total CD4+Foxp3+ Tregs in eWAT (Figure 5, B and C). The increased fraction of CD4+GFP+ cells as well as total CD4+Foxp3+ cells in COX-2–KO WAT enhanced the γδT cell population and increased the CD206+ macrophage fraction (Figure 5, D–H). Consistent with this, adoptive transfer of Tregs restored insulin and glucose tolerance in COX-2–KO mice (Figure 5, I and J), indicating that resident Tregs are indispensable for the antiinflammatory and antidiabetic effects of COX-2 in adipocytes.
Figure 3. Deficiency of COX-2 in adipocytes reduces Treg frequency and type 2 immune response in AT. (A–I) The eWAT samples were collected from 6-month-old male COX-2–KO and control (Ctrl) mice (n = 5–14/group); the stromal vascular fraction of AT was used for flow cytometry analysis. (A) The fraction of resident CD4+Foxp3+ cells was decreased in eWAT of COX-2–KO mice compared with that of Ctrl mice. (B and C) The percentage of CD4+ Foxp3+ cells in total CD4+ cells was decreased in eWAT of COX-2–KO mice compared with that of Ctrl mice. COX-2–KO mice had reduced a Siglec-5–CD11b+CD206+ population (D and E) and decreased proportion of CD11b+CD206+ in CD11b+ cells (F) in eWAT. COX-2 deficiency led to an increase in the γδ T+CD3+ cell population (G and H) and in the proportion of γδ T+CD3+ cells in total CD3+ cells (I) in eWAT. (J) COX-2–KO downregulated mRNA levels of Foxp3, GATA-3 as well as COX-2 in eWAT while upregulating levels of IL-1β and IFN-γ in eWAT despite no significant effect on IL-10, IL-6, and TNF-α. (K and L) The culture medium (CM) from primary COX-2–KO adipocytes decreased the fraction of CD4+Foxp3+ cells and suppressed the percentage of Ki67+ Tregs in total Tregs compared with Ctrl medium. AT Tregs were isolated from AT and treated with the CM from COX-2–KO and Ctrl primary adipocytes for 24 hours. n = 4/group. (M) The medium from primary COX-2–KO adipocytes decreased mRNA levels of Foxp3, Gata3, Il10, and Hpgd without significant effects on Tgfβ1 in AT Tregs. (B, C, E, F, and H–M) The t test was used to analyze data for these studies. All data are presented as mean ± SEM. * P < 0.05; ** P < 0.01.
Adipocyte COX-2 promotes Treg proliferation through PGE₂. To dissect the role of adipocyte COX-2 in regulating resident Tregs, we analyzed the production of PGs in COX-2–KO and control primary adipocytes. COX-2 depletion suppressed the secretion of PGE₂ and PGI₂, but not PGD₂, in adipocytes (Figure 6A and Supplemental Figure 3K), implying a PG-mediated paracrine mechanism. By treating AT Tregs with different doses of PGE₂, PGI₂, and PGD₂, we found that PGE₂, but not PGD₂ or PGI₂,
significantly elevated the number of CD4+Foxp3+ Tregs in a dose-dependent manner (Figure 6B). Consistent with this, the treatment of 100 nM PGE2 elevated the proportion of Ki67-positive CD4+Foxp3+ Tregs in total Tregs (Figure 6C), suggesting that PGE2 may mediate the promoting effect of COX-2 on Treg proliferation.

Given that PGE2 activates PKA, ERK1/2, Akt, and CaMKII in a variety of cell types (31–34), we treated differentiated Tregs with different doses of PGE2 for 1 hour. PGE2 treatment stimulated phosphorylation of PKA substrate and CaMKII, but not ERK1/2 and Akt, in Tregs (Figure 6D and Supplemental Figure 3L). Treatment with PGE2 for 1 hour also stimulated phosphorylation of CaMKII in AT Tregs (Figure 6E). In addition, the promoting effect of PGE2 on cell proliferation was abolished by treating the cells with KT 5720, a specific inhibitor of PKA, or with TATCN21, a specific inhibitor of CaMKII, in AT Tregs (Figure 6F). Inhibiting PKA had a blocking effect on PGE2-induced stimulation of CaMKII in differentiated Tregs (Supplemental Figure 3M). In addition, CaMKII-KO Tregs isolated from AT exhibited lower response to PGE2-induced proliferation (Figure 6, G and H, and Supplemental Figure 3N). These findings suggest that PGE2 promotes Treg proliferation through the PKA-CaMKII axis.

PGE2/Treg axis is required for IF-elicited insulin sensitivity. Given the mediatory role of PGE2 in adipocyte COX-2–driven activation of Tregs, we were motivated to investigate whether PGE2 mediates COX-2–elicited beneficial effects under IF conditions. We administered 50 μg/kg PGE2, i.p. for 2 weeks in COX-2–KO mice fed an IF diet (Figure 7, A–E). Although BW was slightly decreased as a result of IF in COX-2–KO mice, PGE2 administration led to significant body mass loss in COX-2–KO mice under both...
IF and Ad conditions (Figure 7A). In addition, while IF had no significant effect on AT Treg populations and glucose and insulin tolerance in COX-2–KO mice, the reduced beneficial effects were improved by PGE2 treatment (Figure 7, B–E), indicating that PGE2 is downstream of adipocyte COX-2 and plays a critical role in COX-2–mediated metabolic improvement.

We also asked if PGE2 improves insulin sensitivity through induction of Tregs. We injected CD25 neutralizing antibody for 14 days to block Treg function in HFD C57BL/6 mice during PGE2 treatment. Administration of PGE2 increased the population of Foxp3+ Tregs in a dose-dependent manner (B), and treatment of 100 nM PGE2 induced proliferation of Tregs as indicated by the staining of Ki67 (C). Intracellular Ki67+ and Foxp3+ Tregs were determined by flow cytometry analysis. AT Tregs were treated with DMSO, PGD2, PGE2, or PGI2, with indicated doses for 24 hours. *P < 0.05 compared with the group without treatment. (D) Treatment of PGE2 stimulated activation of PKA and CaMKII in differentiated Tregs in a dose-dependent manner. CD4+-naive T cells were isolated from a single-cell suspension from lymph nodes and spleens and then differentiated into CD4+Foxp3+ Tregs. Differentiated Tregs were treated, or not, with PGE2 for 1 hour. Representative data from 3 independent experiments are reported. (E) PGE2 treatment stimulated phosphorylation of CaMKII in AT Tregs. n = 3/group. (F) Inhibiting PKA by 5 μM KT 5720 or inhibiting CaMKII by 5 μM TATCN21 suppressed PGE2-induced proliferation of AT Tregs. AT Tregs were treated with KT 5720 or TATCN21 for 1 hour, followed by co-treatment with PGE2 for 24 hours. n = 3/group. CaMKIIγ deficiency blocked PGE2-stimulated CD4+Foxp3+ Treg proliferation, indicated by Ki67 expression (G) and total Treg fraction (H). Primary Tregs were isolated from AT of CaMKIIγ-KO and WT mice and treated with 100 nM PGE2 for 24 hours, followed by flow cytometry analysis. (A–C) The t test was used for data analysis. (F–H) ANOVA was used for data analysis. Data are reported as mean ± SEM. *P < 0.05; **P < 0.01.

Figure 6. Adipocyte COX-2 promotes resident Treg proliferation through PGE2. (A) COX-2 deficiency suppressed the secretion levels of PGE2 and PGI2 in primary adipocytes. COX-2–KO and control (Ctrl) primary adipocytes were changed to fresh medium and cultured for 2 hours. Medium was collected and used to determine the levels of PGE2 and PGI2, using an ELISA kit. (B, C, E, and F) AT Tregs were isolated from AT for these studies. Treatment of PGE2 but not PGD2 and PGI2 increased the population of Foxp3+ Tregs in a dose-dependent manner (B), and treatment of 100 nM PGE2 induced proliferation of Tregs as indicated by the staining of Ki67 (C). Intracellular Ki67+ and Foxp3+ Tregs were determined by flow cytometry analysis. AT Tregs were treated with DMSO, PGD2, PGE2, or PGI2, with indicated doses for 24 hours. *P < 0.05 compared with the group without treatment. (D) Treatment of PGE2 stimulated activation of PKA and CaMKII in differentiated Tregs in a dose-dependent manner. CD4+-naive T cells were isolated from a single-cell suspension from lymph nodes and spleens and then differentiated into CD4+Foxp3+ Tregs. Differentiated Tregs were treated, or not, with PGE2 for 1 hour. Representative data from 3 independent experiments are reported. (E) PGE2 treatment stimulated phosphorylation of CaMKII in AT Tregs. n = 3/group. (F) Inhibiting PKA by 5 μM KT 5720 or inhibiting CaMKII by 5 μM TATCN21 suppressed PGE2-treatment–induced proliferation of AT Tregs. AT Tregs were treated with KT 5720 or TATCN21 for 1 hour, followed by co-treatment with PGE2 for 24 hours. n = 3/group. CaMKIIγ deficiency blocked PGE2-stimulated CD4+Foxp3+ Treg proliferation, indicated by Ki67 expression (G) and total Treg fraction (H). Primary Tregs were isolated from AT of CaMKIIγ-KO and WT mice and treated with 100 nM PGE2 for 24 hours, followed by flow cytometry analysis. (A–C) The t test was used for data analysis. (F–H) ANOVA was used for data analysis. Data are reported as mean ± SEM. *P < 0.05; **P < 0.01.
Figure 7. The PGE2/Treg axis is indispensable for the antiinflammatory and insulin-sensitizing effects of IF. HFD-fed COX-2–KO mice were fed on an IF schedule or Ad for 4 weeks. Two weeks after IF, mice were injected with PGE2 or vehicle (Veh) for 2 weeks. (A) PGE2 administration resulted in significantly decreased body mass of COX-2–KO mice under both IF and Ad conditions. n = 5–8/group. Treatment with PGE2 restored the AT Treg population (B) and the proportion of Tregs in CD4+ cells (C) in COX-2–KO mice under both IF and Ad conditions. n = 4/group. PGE2 administration improved glucose (D) and insulin (E) tolerance in COX-2–KO mice under both IF and Ad conditions. *P < 0.05 and **P < 0.01 for Veh vs. PGE2 with Ad diet; ∗P < 0.05 for Ad vs. IF with Veh treatment; ∗∗P < 0.05 and ∗∗∗P < 0.01 for IF Veh vs. IF PGE2. HFD-fed C57BL/6 mice were administered CD25 neutralizing antibody for 2 days, followed by PGE2 injection. (F) Blocking the Treg pathway had no significant effect on the antiobesity effect of PGE2, as indicated by the body mass. n = 5–8/group. (G and H) Neutralization of CD25 diminished the inducing effects of PGE2 on the AT Treg population. *P < 0.05 and **P < 0.01 for Ctrl vs. anti-CD25 (aCD25); $P < 0.05 and $$P < 0.01 for aCD25 vs. PGE2, aCD25. (K) Working model. ANOVA was used to analyze the data in this figure. All data are reported as mean ± SEM. LN, lymph node.
Discussion

Caloric restriction promotes weight loss, improves health, and extends lifespan in adult humans and rodents with obesity (35–38). IF is an alternative to continuous caloric restriction that cycles between fasting and nonfasting over a defined period and has been attracting increased attention as an effective approach for weight loss, WAT browning, and improvement of insulin sensitivity (3–5, 39–41). However, the precise mechanisms underlying the beneficial effects of IF are incompletely understood. Our study demonstrates that adipocyte COX-2 is induced by IF and mediates IF-induced CD4+Foxp3+ Treg proliferation and IF-improved inflammation in AT through PGE_2 (Figure 7K). In addition, PGE_2 promotes Treg proliferation via a CaMKII-dependent mechanism (Figure 7K). Our results reveal that adipocyte COX-2 is a promising therapeutic target for the treatment of obesity and its associated diseases.

COX-2 has been considered a key regulator of adipose inflammation and insulin resistance (20–23). However, the physiological signals that drive the activation of COX-2 in adipocytes remain largely unknown. COX-2 expression is restricted under basal conditions in adipocytes and is induced by various environmental stimuli such as adrenoceptor agonists (20). In addition, COX-2 expression is tightly associated with lipolysis, a cellular process controlled by adrenergic signaling in adipocytes (18, 21, 42). In the present study, we found that COX-2 expression in AT is suppressed by obesity in humans and in rodents and is restored by alternate-day fasting (Figure 1). In support of this, IF promotes production and release of COX-2 PG products from adipocytes, including PGE_2 and PGI_2 (Figure 2, D and E). As a result, COX-2 senses fasting and overfeeding in adipose tissue and serves a key player of adipose tissue microenvironment (Figures 4 and 5).

The beneficial effects of IF on insulin sensitivity and antiinflammation were diminished in mice lacking COX-2 in adipocytes, which is likely independent of an antiobesity effect (Figure 4), indicating that adipocyte COX-2 senses fasting and refeeding and mediates the beneficial effects of IF. Consistent with previous observations in adipocyte-specific COX-2–overexpressed mice (43), we also observed the antiobesity property of COX-2 in the present study (Figure 4); however, the underlying mechanisms are currently unclear. We also observed that COX-2 was expressed in AT of female rodents and its expression levels also were suppressed by obesity in humans (Figure 1). Whether COX-2 exerts an antiobesity effect in female rodents and humans remains to be addressed.

COX-2 promotes energy metabolism, such as beige adipocyte formation (18, 26, 44–46). PGE_2, PGI_2, or PGD_2 induces beige adipogenesis yet has no significant effect on the activation of differentiated beige adipocytes (26), suggesting that PG promotes progenitor cell commitment to beige adipogenesis rather than activation of adipocytes. IF has been linked to beige adipogenesis in previous studies (3). However, it is unclear whether adipocyte COX-2 contributes to IF-induced white fat browning. COX-2 deficiency suppresses thermogenic gene expression under IF conditions with little effect under normal diet conditions (Supplemental Figure 3I). The remarkable induction of adipose COX-2 in IF-treated mice may explain this difference. In support of this, mTORC1 inactivation induces COX-2 expression and promotes beige adipocyte formation (26). Of note, adipocyte COX-2 only contributes 20%–30% of local PG production within AT (Figure 2, D and E). The contribution of adipocytes to the local PGs was significantly enhanced during fasting or starvation (Figure 2, D and E). Other metabolites, including fermentation products acetate and lactate and cytokines such as VEGF, mediate IF-elicited thermogenesis by targeting beige adipocytes and resident macrophages, respectively (3, 4). Our study suggests a new mechanism underlying IF-induced improvement in AT inflammation.

Although all 3 PGs (i.e., PGE_2, PGD_2, and PGI_2) can facilitate beige adipocyte differentiation (26), only PGE_2 exerts Treg-inducing effects by regulating its proliferation in white fat (Figure 6). This observation is supported by the recent finding that enrichment of PGE_2 favors the immune-suppressive effects of adipose resident Tregs through its derived metabolite 15-keto-PGE_2 (47). In agreement with the antiinflammatory action of PGE_2 (17, 23, 48), we found that PGE_2 promotes Treg proliferation but not differentiation within AT. Our results are consistent with the findings of Sharma, Baratelli, and colleagues (49) that PGE_2 induces Foxp3 expression and Treg function in human lymphocytes and in lung cancer. In addition, AT Tregs use PGE_2 as a substrate to generate PPARγ ligand 15-keto-PGE_2 with hydroxyprostaglandin dehydrogenase (HPGD) to maintain AT homeostasis (47). Consistent with this, HPGD expression in Tregs was suppressed by the medium from COX-2–KO adipocytes, compared with HPGD expression in the control sample (Figure 3M), suggesting that adipocytes may be an important source of PGE_2 that promotes the immune suppressive activity of Tregs. It is unaddressed whether PGE_2 activates CD206+ macrophages and...
decreases γδT cell populations through regulation of Tregs. Given that Tregs promote the polarization of macrophages to an M2 phenotype by releasing cytokine IL-10 (50, 51), it is possible that PGE₂ via Tregs alternatively activates CD206⁺ macrophages.

Notably, the effects of PGE₂ on Tregs are still under debate. Some studies have shown that PGE₂ induces Foxp3⁺CD4⁺CD25⁺ regulatory T cells in lung and in vitro, inhibiting effector T cell responses (52–54). In human lymphocytes, PGE₂ appears to induce Foxp3 expression and Treg function (49). However, PGE₂ was also reported to inhibit Treg differentiation via the EP2-cAMP/PKA signaling pathway (55). Consistent with the mediatory role of cAMP/PKA pathway in PGE₂ action on T cells (56, 57), we observed that PGE₂ treatment activated PKA and subsequently stimulated CaMKII activation and Treg proliferation (Figure 6F). Consistent with this, CaMKII-KO Tregs had an impaired response to PGE₂ in terms of proliferation (Figure 6, G and H). The communication between adipocytes and Tregs is crucial for Treg proliferation, which also explains the relatively high percentage of Tregs (24%) in total CD4⁺ T cells in AT (Figure 3C) that we observed. Downregulation of COX-2 may be responsible for the decrease in the Treg fraction and subsequent adipose inflammation in obesity (Figure 4D). In contrast, activating the Pgs2 gene in adipocytes provides an approach to restoring AT Tregs and improving AT inflammation.

IF is suggested to be an effective way to improve adipose function and glucose homeostasis through targeting COX-2 and elevating PGE₂ levels in AT (Figure 4D). On the other hand, while acute PGE₂ levels have antiobesity and antiinflammatory effects in AT, whether chronic treatment of PGE₂ potentially causes unwanted effects such as fever, increased metabolic rate, changes in activity level, systemic inflammation or pain, or reduced appetite and food intake necessitates further clarification.

In summary, our data show for the first time, to our knowledge, that adipocyte-derived PGE₂ serves as a paracrine signal that promotes resident Treg proliferation by activating the PKA/CaMKII pathway. In addition, adipocyte-derived PGE₂ mimics IF to elicit metabolic benefits, including Treg proliferation, type 2 inflammation, and insulin sensitivity. Our study shows that the COX-2/PGE₂ axis in adipocytes is a check-point of AT inflammation in obesity. Moreover, this work provides critical insight into the mechanisms by which lipokines and immune cell populations contribute to IF-related mediation of obesity-related illness.

**Methods**

**Materials.** Antibodies (antibody number) against the following were obtained from Cell Signaling Technology: COX-1 (4841), COX-2 (12282), PPARγ (2443), ERK p44/42 (9102), p-ERK P44/42 (4377), Akt (9272), p-Akt (T308) (9275), p-Akt (S473) (4051), and PKA (9621). CaMKII (sc-5306) and p-CaMKII (sc-32289) were from Santa Cruz Biotechnology. Polyclonal antibody to adiponectin and anti-tubulin were provided in-house as described previously (58). The anti-UCP1 (ab23841) was purchased from Abcam. PGD₂, PGE₂, and PGI₂ were obtained from Cayman Chemical Company; KT 5720 from Sigma-Aldrich; and TATCN21 from Millipore.

**Human study.** Samples of visceral AT were obtained from 21 Chinese men and women. Ten participants had BMI >27 kg/m² (obese/overweight group) and had undergone varicocelectomy or hysterectomy, and 11 had BMI <25 kg/m² (control group) and had undergone varicocelectomy, salpingostomy, laparotomy, hysterectomy, debulking surgery, or myomectomy at Baodi Clinical College, Tianjin Medical University, Tianjin, China. Patients with cancer and other chronic inflammatory conditions were excluded. Patients’ baseline characteristics, including sex, age, BMI, BW, waist circumference, hip circumference, medications, and other comorbidities, are summarized in Supplemental Table 1.

The visceral AT samples were obtained at the site of incision in the abdomen. Tissue specimens were immediately washed in saline buffer, snap frozen in liquid nitrogen and stored at −80°C until use. The tissue samples from visceral fat were used for Western blot analysis and RT-PCR. PCR primers are listed in the Supplemental Table 2.

**Animals.** The COX-2–floxed mice were provided by Harvey R. Herschman at the University of California at Los Angeles. Adipocyte–COX-2–specific KO mice were generated by crossing COX-2–floxed mice with adiponectin cre mice (Jackson Laboratory, catalog 10803). COX-2–floxed littermates were used as controls. The KO efficiency was confirmed in AT and other tissues by Western blot analysis and RT-PCR. We purchased C57BL/6 mice from Jackson Laboratory (catalog 000664). Unless otherwise noted, male mice were used for all experiments. Foxp3-eGFP mice (Jackson Laboratory, catalog 006772) were provided by Sarah Adams at the University of New Mexico Health Sciences Center (UNMHSC), and CaMKII-KO mice were originally from Wendong Huang’s laboratory at the City of Hope. Animals were housed in a
specific pathogen-free barrier facility with a 12-hour light/12-hour dark cycle with free access to food and water. For the HFD challenge study, 6-week-old mice were fed a NCD provided by the animal facility at UNMHSC or a HFD (45% kcal fat) from Research Diets Inc. (catalog DI24510) for 8 or 16 weeks, unless otherwise specified.

**Intermittent fasting.** We fed 6-week-old male COX-2–KO and control mice a NCD or HFD for 8 weeks and then randomly grouped them to either the Ad group or IF group. The Ad mice were allowed unrestricted access to their assigned diet, whereas the IF group was fasted for 24 hours and then fed during alternating 24-hour periods of free access to food. The alternate-day fasting was repeated for 3 or 15 cycles. Mice in the IF group were started with 24-hour fasting (10 am) followed by a 24-hour refeeding. The mice in the IF group were euthanized at the end of refeeding (10 am) for tissue sample collection after certain cycles of fasting and refeeding. Similar to the IF group, Ad mice were transferred into a new cage at 10 am every day. The tissue samples were collected during the light cycle (10 am) for both IF and Ad groups.

**Measurement of PG release.** To measure PG levels in tissue explants, 3-month-old male mice underwent 3 cycles of IF or Ad, and 2 types of fat pads, including eWAT and iWAT, were harvested and dissected. A tissue sample (~50 mg) was plated in 0.5 mL of medium (CaCl₂, 1.28 mM; MgSO₄, 1.2 mM; NaHCO₃, 25 mM; HEPES, 15 mM; BSA 0.5%; α-glucose, 5 mM; and penicillin/streptomycin 1%) and incubated at 37°C, 5% CO₂ for 8 hours. Media were then collected and centrifuged at 2300g for 5 minutes at 4°C, and the supernatant was snap frozen. The concentration of PGs, including PGE₂, PGD₂, and PGI₂, in the media was determined using enzyme immunoassay kits according to the manufacturer’s protocol (Cayman Chemical), as described in our previous study (26). The secretion of PGE₂, PGD₂, and PGI₂ was normalized using wet tissue mass. To measure the levels of secreted PGs in primary adipocytes, preadipocytes from iWAT were cultured and differentiated into adipocytes, as described previously (59). Differentiated adipocytes were starved for 4 hours in 0.4% BSA/DMEM, washed with PBS, and incubated with fresh DMEM containing 1% BSA for 2 hours. Culture medium was collected and used to determine the secretion levels of PGE₂, PGD₂, and PGI₂, that were normalized by the total protein level of cells.

**Administration of PGE₂ or anti-CD25.** PGE₂ was dissolved in 100% DMSO and diluted in 0.9% sodium chloride to reach the concentration of 5 μg/mL. We fed 8-week old COX-2–KO mice an HFD for 8 weeks and then randomly grouped the mice into Ad and IF groups. Two weeks after IF, mice were administered 50 μg/kg PGE₂ via i.p. injection every other day for 2 weeks. For the neutralization of CD25 to block Treg function, 8-week-old C57BL/6 mice were fed an HFD for 8 weeks and then administered neutralizing antibody anti-mouse CD25 (IL-2Ra) or IgG1 isotype control anti-trinitrophenol (Bio X Cell) via i.p. injection every other day for 2 weeks starting 2 days before PGE₂ treatment. The mice were then euthanized, and tissue samples from epididymal and inguinal fat were collected for flow cytometry and RT-PCR analyses.

**Primary culture and differentiation of adipocytes.** Primary stromal vascular fractions (SVFs) from iWAT of 3-week-old COX-2–KO and control mice were isolated, cultured, and differentiated into adipocytes according to the procedure described previously (59). Day-6 differentiated primary COX-2–KO and control adipocytes were cultured with a fresh differentiation medium for 24 hours. The medium was collected and used for the determination of PG levels. In addition, the medium was also used to treat primary Tregs isolated from AT (see Treatment of primary Tregs).

**Flow cytometry.** The suspended SVFs from adipose depots were fixed, Fc blocked, and stained with conjugated antibodies, including anti-CD45 (Biolegend), anti-Siglec-5 (BD Pharmingen), anti-CD11b (eBioscience), and anti-CD206 (eBioscience) to identify macrophage and eosinophil subsets. The Treg populations were stained with conjugated antibodies, including anti-CD4 and anti-Foxp3 (eBioscience). Ki67 (eBioscience) was used to mark the proliferating cells. The γδ T cell populations were Fc blocked and labeled with antibodies to peridinin chlorophyll protein complex–conjugated anti-CD3 (Biolegend), and antigen-presenting cell–conjugated anti-γδ T cell receptor (eBioscience) by fixation. Flow cytometry analysis was performed on an acoustic focusing cytometer Attune NxT (Invitrogen), and the data were analyzed by FlowJo software as described in our previous studies (2, 60).

**Adaptive Treg transfer.** Foxp3-eGFP mice were used as the donor mice for immune cell transfer experiments (47, 61). We administered 50 μg of Treg-Protector (Biolegend) through i.v. injection into the donor mice 30 minutes before harvesting lymphoid organs, to protect against cell death. Mouse CD4⁺CD25⁺ Tregs were isolated from a single-cell suspension of lymph nodes and spleens by magnetic-activated cell sorting using a CD4⁺CD25⁺ Regulatory T Cell Isolation Kit (Miltenyi Biotec) with a 2-step procedure: positive selection of CD4⁺CD25⁺ cells after negative depletion of non-CD4⁺ cells, as described previously (62). The
CD4+GFP+ cells were selected from the isolated CD4+CD25+ cells and i.p. injected (1 × 10^5 cells/mouse) into male COX-2–KO and control mice fed an HFD for 8 weeks. At 14 days after injection, the recipients underwent glucose and insulin tolerance tests, as described previously (63). BW was measured as described in Results. The CD4+Foxp3 (GFP)+ Tregs and γδT cells in AT were analyzed using flow cytometry.

**Treatment of primary Tregs.** For the treatment of AT Tregs, CD4+CD25+ T cells were isolated from eWAT stromal vascular fraction of 2-month-old mice by magnetic-activated cell sorting as described in the previous paragraph. Isolated CD4+CD25+ cells were cultured for 24 hours, followed by treatment with a different-dose of PG for another 24 hours. For the inhibitor experiment, the cells were pretreated with 5 μM KT 5720, a specific inhibitor of PKA, or 5 μM TNTCN21, a specific inhibitor of CaMKII, for 1 hour prior to co-treatment with 100 nM PGE. For CaMKII phosphorylation study, cells were treated with or without 100 nM PGE, for 1 hour before flow cytometry analysis. In the treatment of AT Tregs with the medium from adipocytes, the medium was collected as described for primary culture and then used to treat AT Tregs for 2 days. After treatment, Tregs underwent flow cytometry analysis. For the signaling study, naive CD4+ T cells were isolated from a single-cell suspension of lymph nodes and spleens by depleting non-CD4+ and regulatory T cells (B220+, CD8+, and CD25+ cells) and positive selecting CD62L+ cells using magnetic beads. Naive T cells were cultured in 10% FBS-PREMI 1640 medium in the presence of 2 ng/mL TGF-β, 10 ng/mL IL-2, and 5 μg/mL anti–IFN-γ on anti–CD3/CD28–coated 24-well plates for 4 days. One day after differentiation, the differentiated Tregs were treated with or without PGE, with different doses. Cells were harvested for Western blot analysis.

H&E staining, liver triglyceride content, real-time PCR, Western blot, glucose and insulin tolerance test and insulin signaling assay, and dual-energy X-ray absorptiometry scanning are detailed in the Supplemental Methods. See complete unedited blots in the supplemental material.

**Statistics.** Statistical analysis of the data was performed using a 2-tailed Student’s t test between 2 groups or the 1-way ANOVA for a comparison of more than 2 groups. All the results are presented as the mean ± SEM, and P < 0.05 was considered statistically significant.

**Study approval.** All animal experimental protocols were reviewed and approved by the Animal Care Committee of the University of New Mexico Health Sciences Center. The human study complied with the Helsinki Declaration for investigation of human participants and received ethical approval from the IRBs of Baodi Clinical College, Tianjin Medical University. All participants provided written informed consent.

**Author contributions**
ML designed the project. XOY designed the adoptive transfer of Tregs and provided technical support for the Treg analysis for this project. FL served as a consultant on this project. LL, XM, CY, and YF completed the human study. CW, XZ, LL, YL, XY, XD, HL, LW, LERF, and LY conducted the experiments. CW, XZ, YL, HL, XD, WH, and ML analyzed the results. CW drafted the Methods section. ML is the guarantor of this study and wrote the manuscript. FL, XOY, and LERF edited the manuscript. All authors reviewed and approved the manuscript.

**Acknowledgments**
We thank Harvey R. Herschman at the University of California at Los Angeles for providing us COX-2–floxed mice. We thank Lily Dong at University of Texas Health Science Center at San Antonio for providing the antibodies against adiponectin and tubulin for this study. We thank the Autophagy, Inflammation, and Metabolism Center at UNMHSC for providing the ChemiDoc MP Imaging System for this study. We also thank Sarah Adams for providing us Foxp3-eGFP mice. We are thankful for the support from Yan Long at Luhe Hospital, Beijing, China, during the human study. This work is supported by an R01 award (DK110439 PI to ML) from the National Institute of Diabetes and Digestive and Kidney Diseases; P20 Award (GM121176 [program director: Vojo Deretic; multiple principle investigators (mPIs): ML and XOY]); Grant-in-aid Award (15GRNT24940018 [PI: ML]) from the American Heart Association; an Innovative Basic Science Award (1-17-IBS-261 [PI: ML]) from the American Diabetes Association; an R01 Award (HL148337 to XOY) from the National Heart, Lung, and Blood Institute; a Clinical and Translation-al Science Center pilot award (PI: ML); a Center of Biomedical Research Excellence pilot award associated with P30 (P30GM103400 [PI: J. Liu; mPI: ML]); and a University of New Mexico Comprehensive Cancer Center, UNMHSC, pilot award (PI: ML). This project was supported in part by the Dedicated Health Research Funds from the University of New Mexico School of Medicine.
Address correspondence to: Meilian Liu, MSC08-4670, 1 University of New Mexico, Albuquerque, New Mexico 87131, USA. Phone: 210.630.8913; Email: meilianliu@salud.unm.edu.